IL148166A0 - Drug for treating fractures - Google Patents

Drug for treating fractures

Info

Publication number
IL148166A0
IL148166A0 IL14816600A IL14816600A IL148166A0 IL 148166 A0 IL148166 A0 IL 148166A0 IL 14816600 A IL14816600 A IL 14816600A IL 14816600 A IL14816600 A IL 14816600A IL 148166 A0 IL148166 A0 IL 148166A0
Authority
IL
Israel
Prior art keywords
drug
treating fractures
fractures
treating
Prior art date
Application number
IL14816600A
Other languages
English (en)
Original Assignee
Royal Alexandra Hosp Children
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Royal Alexandra Hosp Children filed Critical Royal Alexandra Hosp Children
Publication of IL148166A0 publication Critical patent/IL148166A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL14816600A 1999-08-19 2000-08-17 Drug for treating fractures IL148166A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPQ2325A AUPQ232599A0 (en) 1999-08-19 1999-08-19 Drug for treating fractures
PCT/AU2000/000982 WO2001013922A1 (en) 1999-08-19 2000-08-17 Drug for treating fractures

Publications (1)

Publication Number Publication Date
IL148166A0 true IL148166A0 (en) 2002-09-12

Family

ID=3816500

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14816600A IL148166A0 (en) 1999-08-19 2000-08-17 Drug for treating fractures

Country Status (16)

Country Link
EP (1) EP1214079A4 (xx)
JP (1) JP2003507426A (xx)
KR (1) KR20020027562A (xx)
CN (1) CN100345548C (xx)
AU (1) AUPQ232599A0 (xx)
BR (1) BR0013416A (xx)
CA (1) CA2381302A1 (xx)
HK (1) HK1048441B (xx)
HU (1) HUP0202396A3 (xx)
IL (1) IL148166A0 (xx)
NO (1) NO20020784L (xx)
NZ (1) NZ517538A (xx)
PL (1) PL353485A1 (xx)
SK (1) SK2382002A3 (xx)
WO (1) WO2001013922A1 (xx)
ZA (1) ZA200202160B (xx)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1365769B1 (en) * 2001-02-06 2011-01-26 The Sydney Children's Hospitals Network (Randwick and Westmead) (incorporating The Royal Alexandra Hospital for Children) A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis
AU2002244520B2 (en) * 2001-04-03 2007-05-24 The Royal Alexandra Hospital For Children A drug for use in bone grafting
AUPR553701A0 (en) * 2001-06-07 2001-07-12 Royal Alexandra Hospital For Children, The A device for the delivery of a drug to a fractured bone
ES2561463T3 (es) * 2003-08-21 2016-02-26 Addbio Ab Dispositivo de implante recubierto con bisfosfonato y método para el mismo
CA2539359A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bisphosphonate
ITMI20040218A1 (it) * 2004-02-10 2004-05-10 Abiogen Pharma Spa Uso di neridronato sodico per promuovere la neoformazione ossea
ITMI20040641A1 (it) * 2004-03-31 2004-06-30 Tb Technology S R L Composizioni bioadesive bifunzionali per implantologia orale
AR048742A1 (es) * 2004-12-22 2006-05-24 Gador Sa Sistema de aplicacion de medicamentos intra-oral
ES2379485T3 (es) * 2005-10-27 2012-04-26 Thommen Medical Ag Implante dental y procedimiento para su fabricación
US8882740B2 (en) 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR8107560A (pt) * 1981-11-19 1983-07-05 Luiz Romariz Duarte Estimulacao ultra-sonica da consolidacao de fraturas osseas
SK74594A3 (en) * 1991-12-17 1995-01-12 Procter & Gamble Pharma Treatment for treating of osteoporosis
EP0600834A1 (en) * 1992-11-30 1994-06-08 Ciba-Geigy Ag Use of methanebisphosphonic acid derivatives for the manufacture of a medicament for fracture healing
AU670337B2 (en) * 1992-11-30 1996-07-11 Novartis Ag Use of certain methanebisphosphonic acid derivatives in fracture healing
WO1994014455A1 (en) * 1992-12-23 1994-07-07 Merck & Co., Inc. Bisphosphonate/estrogen therapy for treating and preventing bone loss
US5403829A (en) * 1993-03-24 1995-04-04 Leiras Oy Use of bisphosphonates in endo-osteal bone surgery
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
GB9408775D0 (en) * 1994-05-04 1994-06-22 Ciba Geigy Ag Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration
US5616571A (en) * 1995-06-06 1997-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy
WO1996039150A1 (en) * 1995-06-06 1996-12-12 Merck & Co., Inc. Bisphosphonate therapy for bone loss associated with rheumatoid arthritis
US5853759A (en) * 1996-05-17 1998-12-29 Merck & Co.. Inc. Effervescent alendronate formulation
GB9613722D0 (en) * 1996-06-28 1996-08-28 Univ Liverpool Chemical compounds

Also Published As

Publication number Publication date
KR20020027562A (ko) 2002-04-13
ZA200202160B (en) 2003-08-27
NZ517538A (en) 2003-07-25
CA2381302A1 (en) 2001-03-01
JP2003507426A (ja) 2003-02-25
NO20020784D0 (no) 2002-02-18
WO2001013922A1 (en) 2001-03-01
PL353485A1 (en) 2003-11-17
BR0013416A (pt) 2002-04-30
HUP0202396A3 (en) 2005-02-28
CN1370071A (zh) 2002-09-18
CN100345548C (zh) 2007-10-31
HK1048441A1 (en) 2003-04-04
SK2382002A3 (en) 2002-09-10
HUP0202396A2 (hu) 2002-11-28
HK1048441B (zh) 2008-02-22
AUPQ232599A0 (en) 1999-09-09
EP1214079A4 (en) 2004-03-24
NO20020784L (no) 2002-02-18
EP1214079A1 (en) 2002-06-19

Similar Documents

Publication Publication Date Title
HUP0200556A2 (en) Medicament for treating diabetes
HK1200316A1 (en) Therapeutic microfoams
IL138784A0 (en) Treatment for diabetes
PL350167A1 (en) Medicament for treating hypertension
GB9930570D0 (en) Therapy
GB9925136D0 (en) Novel treatment
GB9907243D0 (en) Therapy
PL349347A1 (en) Novel treatment
IL148166A0 (en) Drug for treating fractures
GB9900222D0 (en) Therapeutic compounds
HU9902296D0 (en) Pharmaceutical composition for treating caltification
GB0020261D0 (en) Therapeutic treatment
HUP0105469A3 (en) Therapeutic drugs comprising pyrroloazepines for treating intermittent claudication
GB9901505D0 (en) Therapeutic treatment
GB9924980D0 (en) Therapeutic treatment
HU9904711D0 (en) Set for fixation fractures
GB9919721D0 (en) Medical apparatus
GB9908993D0 (en) Treatment
GB9903558D0 (en) Medical treatment
GB9923343D0 (en) Treatment system
GB9924712D0 (en) Therapeutic method
AU142194S (en) Medical treatment apparatus
GB9927106D0 (en) Cancer treatment
GB9908176D0 (en) Cancer treatment
GB9916655D0 (en) Novel treatment